Advertisement

Crohn’s Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies

  • Ersilia M. DeFilippisEmail author
  • Randy Longman
  • Michael Harbus
  • Kyle Dannenberg
  • Ellen J. Scherl
Small Intestine (D Sachar, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Small Intestine

Abstract

Crohn’s disease (CD) is a chronic, systemic, immune-mediated inflammation of the gastrointestinal tract. Originally described in 1932 as non-caseating granulomatous inflammation limited to the terminal ileum, it is now recognized as an expanding group of heterogeneous diseases defined by intestinal location, extent, behavior, and systemic extraintestinal manifestations. Joint diseases, including inflammatory spondyloarthritis and ankylosing spondylitis, are the most common extraintestinal manifestations of CD and share more genetic susceptibility loci than any other inflammatory bowel disease (IBD) trait. The high frequency and overlap with genes associated with infectious diseases, specifically Mendelian susceptibility to mycobacterial diseases (MSMD), suggest that CD may represent an evolutionary adaptation to environmental microbes. Elucidating the diversity of the enteric microbiota and the protean mucosal immune responses in individuals may personalize microbiome-targeted therapies and molecular classifications of CD. This review will focus on CD’s natural history and therapies in the context of epigenetics, immunogenetics, and the microbiome.

Keywords

Microbiome Personalized medicine Inflammatory bowel disease Environmental enteropathy Epigenetics Public health 

Notes

Compliance with Ethical Standard

Conflicts of Interest

Ersilia M. DeFilippis, Randy Longman, Michael Harbus, and Kyle Dannenberg declare that they have no conflicts of interest. Ellen J. Scherl reports grants and research support from Abbott (AbbVie), AstraZeneca, CCFA, Elan, Janssen, Research & Development, JOMS Hopkins University, Mesoblast (formerly Osiris Therapeutics), Millennium Pharmaceuticals, National Institute of Diabetes and Digestive and Kidney (NIDDK), National Institute of Health (NIH), New York CroM’s Foundation, Osiris Therapeutics, Pfizer, Prometheus Laboratories, Salix, UCB, and UCSF-CCFA Clinical Research Alliance; consultancy/advisory board membership with AbbVie, CroM’S and Colitis Foundation of America (CCFA), Entera Health, Evidera, 01 Health Foundation, Janssen, NPS Pharmaceutical, Prometheus, Protagonist Therapeutics, Salix, Seres Health, Shire, SUN FZE, Takeda Pharmaceuticals, and UCB; honoraria from OIHealth Foundation for non-branded speaker’s bureau, Janssen for non-branded speaker’s bureau, ClearView Healthcare Partners for market research; and a patent filed 16 February 2007, titled “E. coli and ileal Crohn’s disease: selective enrichment of ileal mucosa with E. coli of novel phylogeny.”

Human and Animal Rights and Informed Consent

With regard to the authors’ research cited in this paper, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. In addition, all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Crohn BB, Ginzburg L, Oppenheimer GD. Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA. 1984;251:73–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Vermeire S, Van Assche G, Rutgeerts P. Classification of inflammatory bowel disease: the old and the new. Curr Opin Gastroenterol. 2012;28:321–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14:331–7.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.••
    McGovern DPB, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015;149:1163–76. A thorough review and summary of the genome-wide association studies in IBD and the genetic loci that contribute to different phenotypes of the disease.PubMedCrossRefGoogle Scholar
  8. 8.
    Economou M, Pappas G. New global map of Crohn’s disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Feinberg AP, Fallin MD. Epigenetics at the crossroads of genes and the environment. JAMA. 2015;314:1129–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Hugot J-P, Alberti C, Berrebi D, Bingen E, Cézard J-P. Crohn’s disease: the cold chain hypothesis. Lancet. 2003;362:2012–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Malekzadeh F, Alberti C, Nouraei M, Vahedi H, Zaccaria I, Meinzer U, et al. Crohn’s disease and early exposure to domestic refrigeration. PLoS One. 2009;4:e4288.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Ko Y, Kariyawasam V, Karnib M, Butcher R, Samuel D, Alrubaie A, et al. Inflammatory bowel disease environmental risk factors: a population-based case–control study of Middle Eastern migration to Australia. Clin Gastroenterol Hepatol. 2015;13:1453–63. e1.PubMedCrossRefGoogle Scholar
  13. 13.••
    Martin TD, Chan SSM, Hart AR. Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature. Dig Dis Sci. 2015;60:1396–405. Reinforces Crohn’s disease as a chronic environmental enteropathy that poses public health threat.PubMedCrossRefGoogle Scholar
  14. 14.
    Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–17.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee D, Albenberg L, Compher C, Baldassano R, Piccoli D, Lewis JD, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015;148:1087–106.PubMedCrossRefGoogle Scholar
  16. 16.
    Benchimol EI, Mack DR, Guttmann A, Nguyen GC, To T, Mojaverian N, et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol. 2015;110:553–63.PubMedCrossRefGoogle Scholar
  17. 17.••
    Wang M-H, Achkar J-P. Gene-environment interactions in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol. 2015;31:277–82. Emphasizes the interplay between environmental and genetic susceptibilities in producing a variety of phenotypes of Crohn’s disease.PubMedCrossRefGoogle Scholar
  18. 18.
    Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, et al. Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology. 2015;149:1575–86.PubMedCrossRefGoogle Scholar
  19. 19.••
    Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24. Describes the intersection of immunogenetic patterns and signatures in determining the course of IBD.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hill AVS. Evolution, revolution and heresy in the genetics of infectious disease susceptibility. Philos Trans R Soc Lond B Biol Sci. 2012;367:840–9.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Azad AK, Sadee W, Schlesinger LS. Innate immune gene polymorphisms in tuberculosis. Infect Immun. 2012;80:3343–59.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Chiodini RJ, Chamberlin WM, Sarosiek J, McCallum RW. Crohn’s disease and the mycobacterioses: a quarter century later. Causation or simple association? Crit Rev Microbiol. 2012;38:52–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Waddell LA, Rajić A, Stärk KDC, McEWEN SA. The zoonotic potential of Mycobacterium avium ssp. paratuberculosis: a systematic review and meta-analyses of the evidence. Epidemiol Infect. 2015;143:3135–57.PubMedCrossRefGoogle Scholar
  24. 24.
    Naser SA, Sagramsingh SR, Naser AS, Thanigachalam S. Mycobacterium avium subspecies paratuberculosis causes Crohn’s disease in some inflammatory bowel disease patients. World J Gastroenterol. 2014;20:7403–15.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Coulombe F, Divangahi M, Veyrier F, de Léséleuc L, Gleason JL, Yang Y, et al. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med. 2009;206:1709–16.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337:1029–36.PubMedCrossRefGoogle Scholar
  28. 28.
    Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10:387–98.PubMedCrossRefGoogle Scholar
  29. 29.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.PubMedCrossRefGoogle Scholar
  30. 30.••
    Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, et al. Polymorphisms in the toll-like receptor and the IL-23/IL-17 pathways were associated with susceptibility to inflammatory bowel disease in a Danish cohort. PLoS One. 2015;10:e0145302. Examines the role of IL-23/IL-17 and interferon gamma pathways in the pathogenesis of Crohn’s disease.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1090–100.PubMedCrossRefGoogle Scholar
  32. 32.
    Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–41.PubMedCrossRefGoogle Scholar
  33. 33.
    McLean LP, Cross RK, Shea-Donohue T. Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis. Immunotherapy. 2013;5:923–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Lee JS, Tato CM, Joyce-Shaikh B, Gulan F, Cayatte C, Chen Y, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015;43:727–38.PubMedCrossRefGoogle Scholar
  35. 35.
    Sonnenberg GF, Artis D. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med. 2015;21:698–708.PubMedCrossRefGoogle Scholar
  36. 36.
    Desreumaux P. Specific targeting of IL-6 signalling pathway: a new way to treat IBD? Gut. 2000;47:465–6.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:503–16.PubMedCrossRefGoogle Scholar
  39. 39.
    Bellaguarda E, Chang EB. IBD and the gut microbiota—from bench to personalized medicine. wCurr Gastroenterol Rep. 2015;17:15.CrossRefGoogle Scholar
  40. 40.••
    Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–92. Unexplained heterogeneity in Crohn’s disease phenotypes may be explained by differences in the microbiome among affected individuals.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Longman RS, Swaminath A. Microbial manipulation as primary therapy for Crohn’s disease. World J Gastroenterol. 2013;19:1513–6.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.••
    Dogan B, Suzuki H, Herlekar D, Sartor RB, Campbell BJ, Roberts CL, et al. Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation. Inflamm Bowel Dis. 2014;20:1919–32. Examines the dysbiosis and the role of adherent-invasive E. coli in promoting intestinal inflammation and potential therapeutic targets.Google Scholar
  43. 43.
    Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J. 2007;1:403–18.PubMedCrossRefGoogle Scholar
  44. 44.
    Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe. 2013;13:711–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337–41.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Honneffer JB, Minamoto Y, Suchodolski JS. Microbiota alterations in acute and chronic gastrointestinal inflammation of cats and dogs. World J Gastroenterol. 2014;20:16489–97.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kolho K-L, Korpela K, Jaakkola T, Pichai MVA, Zoetendal EG, Salonen A, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110:921–30.PubMedCrossRefGoogle Scholar
  48. 48.
    Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163:367–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415–22.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Baars JE, Nuij VJAA, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012;18:3790–9.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Shanahan F, Targan S. Medical treatment of inflammatory bowel disease. Annu Rev Med. 1992;43:125–33.PubMedCrossRefGoogle Scholar
  53. 53.
    Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol. 1988;83:497–503.PubMedGoogle Scholar
  54. 54.
    Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife. 2013;2:e01202.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Jones JH, Lennard-Jones JE. Corticosteroids and corticotrophin in the treatment of Crohn’s disease. Gut. 1966;7:181–7.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Olaison G, Sjödahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn’s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut. 1990;31:325–8.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Rhodes J, Bainton D, Beck P. Azathioprine in Crohn’s disease. Lancet. 1970;2:1142.PubMedCrossRefGoogle Scholar
  58. 58.
    Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2013;4:CD000545.PubMedGoogle Scholar
  59. 59.
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015.Google Scholar
  61. 61.
    Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, et al. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005;100:75–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–33. quiz 591.PubMedCrossRefGoogle Scholar
  63. 63.
    Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014;43:457–78.PubMedCrossRefGoogle Scholar
  64. 64.
    Loftus EV, Feagan BG, Colombel J-F, Rubin DT, Wu EQ, Yu AP, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008;103:3132–41.PubMedCrossRefGoogle Scholar
  65. 65.
    Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.PubMedCrossRefGoogle Scholar
  66. 66.
    Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114–26.PubMedCrossRefGoogle Scholar
  67. 67.
    Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613–23.PubMedCrossRefGoogle Scholar
  68. 68.
    Parsi MA, Achkar J-P, Richardson S, Katz J, Hammel JP, Lashner BA, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology. 2002;123:707–13.PubMedCrossRefGoogle Scholar
  69. 69.
    Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40–7.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13:522–30. e2.PubMedCrossRefGoogle Scholar
  71. 71.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–83.PubMedCrossRefGoogle Scholar
  72. 72.
    Cominelli F. Inhibition of leukocyte trafficking in inflammatory bowel disease. N Engl J Med. 2013;369:775–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.PubMedCrossRefGoogle Scholar
  74. 74.
    Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.PubMedCrossRefGoogle Scholar
  75. 75.
    Bamias G, Clark DJ, Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets. 2013;14:1490–500.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    James DG, Seo DH, Chen J, Vemulapalli C, Stone CD. Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn’s disease: an open-label pilot study. Dig Dis Sci. 2011;56:1806–10.PubMedCrossRefGoogle Scholar
  77. 77.
    Kothary N, Diak I-L, Brinker A, Bezabeh S, Avigan M, Dal PG. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65:546–51.PubMedCrossRefGoogle Scholar
  78. 78.
    Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579–94.PubMedCrossRefGoogle Scholar
  79. 79.
    Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015;29:565–75.PubMedCrossRefGoogle Scholar
  80. 80.
    Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.PubMedCrossRefGoogle Scholar
  81. 81.
    Löwenberg M, D’Haens G. Next-generation therapeutics for IBD. Curr Gastroenterol Rep. 2015;17:21.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn’s disease. Clin Gastroenterol Hepatol. 2007;5:215–20.PubMedCrossRefGoogle Scholar
  83. 83.
    Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616–24.PubMedCrossRefGoogle Scholar
  84. 84.
    Konijeti GG, Chan AT. Ustekinumab for moderate-to-severe Crohn’s disease. Gastroenterology. 2013;144:846–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28.PubMedCrossRefGoogle Scholar
  86. 86.
    Sedda S, Marafini I, Dinallo V, Di Fusco D, Monteleone G. The TGF-β/Smad system in IBD Pathogenesis. Inflamm Bowel Dis. 2015Google Scholar
  87. 87.
    Monteleone G, Pallone F. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372:2461.PubMedCrossRefGoogle Scholar
  88. 88.
    Krishnan K, Arnone B, Buchman A. Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm Bowel Dis. 2011;17:410–22.PubMedCrossRefGoogle Scholar
  89. 89.
    Dieckgraefe BK, Korzenik JR. Treatment of active Crohn’s disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002;360:1478–80.PubMedCrossRefGoogle Scholar
  90. 90.
    Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim in Crohn’s Disease Study Group. Sargramostim for active Crohn’s disease. N Engl J Med. 2005;352:2193–201.PubMedCrossRefGoogle Scholar
  91. 91.
    Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn’s disease. Aliment Pharmacol Ther. 2005;21:391–400.PubMedCrossRefGoogle Scholar
  92. 92.
    Dejaco C, Lichtenberger C, Miehsler W, Oberhuber G, Herbst F, Vogelsang H, et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn’s disease. Digestion. 2003;68:63–70.PubMedCrossRefGoogle Scholar
  93. 93.
    Colombel JF, Lémann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999;94:674–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.PubMedCrossRefGoogle Scholar
  95. 95.
    Wang Z-K, Yang Y-S, Chen Y, Yuan J, Sun G, Peng L-H. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. World J Gastroenterol. 2014;20:14805–20.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30:51–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991;338:771–4.PubMedCrossRefGoogle Scholar
  98. 98.
    Fichera A, McCormack R, Rubin MA, Hurst RD, Michelassi F. Long-term outcome of surgically treated Crohn’s colitis: a prospective study. Dis Colon Rectum. 2005;48:963–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Gerich ME, McGovern DPB. Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol. 2014;11:287–99.PubMedCrossRefGoogle Scholar
  101. 101.
    Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn’s disease and ulcerative colitis. Can J Gastroenterol. 2008;22:33–6.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.••
    Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015;14:231–45. Describes serological markers and their role in personalizing therapeutic and management decisions in patients with Crohn’s disease.PubMedCrossRefGoogle Scholar
  103. 103.
    Däbritz J, Bonkowski E, Chalk C, Trapnell BC, Langhorst J, Denson LA, et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol. 2013;108:1901–10.PubMedCrossRefGoogle Scholar
  104. 104.
    Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109:994–1004.PubMedCrossRefGoogle Scholar
  105. 105.
    Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, et al. The effect of breathing, movement, and meditation on psychological and physical symptoms and inflammatory biomarkers in inflammatory bowel disease: a randomized controlled trial. Inflamm Bowel Dis. 2015;21:2886–96.PubMedCrossRefGoogle Scholar
  106. 106.
    Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut. 2012;61:459–65.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Ersilia M. DeFilippis
    • 1
    Email author
  • Randy Longman
    • 2
  • Michael Harbus
    • 3
  • Kyle Dannenberg
    • 4
  • Ellen J. Scherl
    • 5
  1. 1.Department of MedicineBrigham and Women’s HospitalBostonUSA
  2. 2.Jill Roberts Center for Inflammatory Bowel Disease, Jill Roberts Institute for Research in Inflammatory Bowel DiseaseNew York Presbyterian Hospital-Weill Cornell Medical CollegeNew YorkUSA
  3. 3.New York Institute of Technology College of Osteopathic MedicineNew YorkUSA
  4. 4.Weill Cornell Medical CollegeNew YorkUSA
  5. 5.Jill Roberts Center for Inflammatory Bowel DiseaseNew York Presbyterian Hospital-Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations